1. Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS mean change from baseline. †Data are mean change from baseline for patients with baseline A1C ≥7.0% who had A1C data at baseline and follow-up. ‡P = for CANA versus DPP-4 inhibitor cohort. §P = for CANA versus SITA cohort. ||P = for CANA versus DPP-4 inhibitor cohort. ¶P = for CANA versus SITA cohort.
Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS mean change from baseline. †Data are mean change from baseline for patients with baseline A1C ≥7.0% who had A1C data at baseline and follow-up. ‡P = for CANA versus DPP-4 inhibitor cohort. §P = for CANA versus SITA cohort. ||P = for CANA versus DPP-4 inhibitor cohort. ¶P = for CANA versus SITA cohort. BP, blood pressure; CANA, canagliflozin; LS, least squares; MET, metformin; RCT, randomized controlled trial; SITA, sitagliptin; SU, sulfonylurea.
Richard E. Pratley, and Eugenio Cersosimo Clin Diabetes 2017;35:
©2017 by American Diabetes Association